Company Overview
Position Overview
Immunome is seeking an Associate Director / Director, Regulatory Affairs CMC, responsible for developing and executing global regulatory CMC strategies across multiple modalities. This individual will manage key deliverables and ensure adherence to accelerated regulatory submission schedules. Reporting into the Senior Director, Regulatory Affairs CMC, the role is responsible for communications and interactions with global regulatory authorities. This person will collaborate cross-functionally with teams including Technical Operations, Quality Assurance, Supply Chain Management, and Project Management to maintain alignment with regulatory CMC strategies and compliance requirements.
Responsibilities
- Develop and execute global regulatory CMC strategies across clinical and commercial stages.
- Serve as the regulatory CMC lead on cross-functional teams, providing strategic input to technical operations, supply chain, quality and project teams.
- Author, review and manage the preparation of high-quality CMC sections for regulatory submission (e.g. IND, CTAs, IMPD, annual reports, pediatric plans, amendments, and marketing applications).
- Lead interactions with global health authorities on CMC topics, including preparation of briefing packages, responses to information requests, and representation at meetings.
- Collaborate with internal and external stakeholders to ensure regulatory compliance and alignment with regulatory CMC strategies.
- Maintain current knowledge of regulations and guidelines (e.g., ICH, FDA, EMA) and keep abreast of changes in the global regulatory environment.
- Support regulatory inspections, as required.
Qualifications
- Bachelor’s degree in a relevant scientific discipline required; advanced degree a plus.
- A minimum of 7 years of relevant pharmaceutical/biotechnology industry experience, including 5+ years in regulatory CMC, or equivalent experience.
- Hands-on experience with CMC submission preparation for small molecules, biologics, and/or antibody-drug conjugates.
- Experience with regulatory CMC strategy development and health authority interactions.
Knowledge and Skills
- Deep understanding of ICH, FDA and EMA guidelines.
- Outstanding communication, analytical, organizational and time management skills.
- Strong written and verbal communication abilities with attention to detail.
- Ability to effectively lead cross-functional teams.
- Flexible work style with a pragmatic approach to rapidly changing priorities.
- Proficiency in submission management software, such as Veeva RIM.
E/E/O
Immunome, Inc. is an equal opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.
E-Verify
Immunome, Inc. is a participant in E-Verify. Please review the following notices: E-Verify Participation Poster | Right to Work Poster (English) | Right to Work Poster (Spanish).
Skills Required
- Bachelor's degree in a relevant scientific discipline
- Advanced degree in a relevant scientific discipline
- Minimum 7 years pharmaceutical/biotechnology experience, including 5+ years in regulatory CMC (or equivalent)
- Hands-on experience preparing CMC submissions for small molecules, biologics, and/or antibody-drug conjugates
- Experience developing regulatory CMC strategy and interacting with health authorities
- Deep understanding of ICH, FDA, and EMA guidelines
- Proficiency in submission management software (e.g., Veeva RIM)
- Outstanding communication, analytical, organizational and time management skills
- Ability to effectively lead cross-functional teams
What We Do
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted therapies designed to improve outcomes for cancer patients. We are advancing an innovative portfolio of therapeutics, drawing on leadership that previously played key roles in the design, development, and commercialization of cutting-edge targeted cancer therapies, including antibody-drug conjugate therapies (ADCs). Our most advanced pipeline programs are varegacestat (formerly AL102), a gamma secretase inhibitor which is currently in a Phase 3 trial for treatment of desmoid tumors; IM-1021, a ROR1-targeted ADC which is currently in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand, which recently received IND clearance. Our pipeline also includes IM-1617, IM-1335, and IM-1340, all of which are preclinical ADCs pursuing undisclosed targets with expression in multiple solid tumors.
.png){kind=logo}
